|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-5-14
|
|
pubmed:abstractText |
DPC168, a benzylpiperidine-substituted aryl urea CCR3 antagonist evaluated in clinical trials, was a relatively potent inhibitor of the 2D6 isoform of cytochrome P-450 (CYP2D6). Replacement of the cyclohexyl central ring with saturated heterocycles provided potent CCR3 antagonists with improved selectivity against CYP2D6. The favorable preclinical profile of DPC168 was maintained in an acetylpiperidine derivative, BMS-570520.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1-(2-((3-(4-fluorobenzyl)piperidin-1...,
http://linkedlifedata.com/resource/pubmed/chemical/Benzyl Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/CCR3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Ccr3 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP2D6,
http://linkedlifedata.com/resource/pubmed/chemical/Phenylurea Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR3,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Chemokine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:BattDouglas GDG,
pubmed-author:BookerShon KSK,
pubmed-author:BostromLori LLL,
pubmed-author:CarterPercy HPH,
pubmed-author:ChristDavid DDD,
pubmed-author:CovingtonMaryanneM,
pubmed-author:DasAnuk MAM,
pubmed-author:DaviesPaulP,
pubmed-author:DeciccoCarl PCP,
pubmed-author:GradenDanielleD,
pubmed-author:HoughtonGregory CGC,
pubmed-author:KarivIlonaI,
pubmed-author:KoSoo SSS,
pubmed-author:McLaughlinErinE,
pubmed-author:NewtonRobert CRC,
pubmed-author:OrlovskyYevgeniyaY,
pubmed-author:PruittJames RJR,
pubmed-author:SolomonKimberly AKA,
pubmed-author:StowellNicole CNC,
pubmed-author:VaddiKrishna GKG,
pubmed-author:VarnesJeffrey GJG,
pubmed-author:WackerDean ADA,
pubmed-author:WadmanEric AEA,
pubmed-author:WelchPatricia KPK,
pubmed-author:YeleswaramSwamyS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2992-7
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17418570-Animals,
pubmed-meshheading:17418570-Benzyl Compounds,
pubmed-meshheading:17418570-Biological Assay,
pubmed-meshheading:17418570-Cells, Cultured,
pubmed-meshheading:17418570-Cytochrome P-450 CYP2D6,
pubmed-meshheading:17418570-Humans,
pubmed-meshheading:17418570-Mice,
pubmed-meshheading:17418570-Pan troglodytes,
pubmed-meshheading:17418570-Phenylurea Compounds,
pubmed-meshheading:17418570-Piperidines,
pubmed-meshheading:17418570-Receptors, CCR3,
pubmed-meshheading:17418570-Receptors, Chemokine,
pubmed-meshheading:17418570-Structure-Activity Relationship
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.
|
|
pubmed:affiliation |
Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543-4000, USA.
|
|
pubmed:publicationType |
Journal Article
|
